1. Introduction
===============

Constant or intermittent chronic pelvic pain (CPP) is a common complaint in women.^\[[@R1]--[@R3]\]^ It often manifests in the pelvic and lower abdominal regions for more than 6 months.^\[[@R4]--[@R7]\]^ CPP often accompanies dysmenorrhoea, dyspareunia, dyschesia, and dysuria.^\[[@R8]--[@R10]\]^ The annual prevalence of CPP is 38 out of every 1000 women aged 15 to 73 years, but only 20% to 25% of them visit the doctor.^\[[@R2],[@R11]\]^ Thus, CPP is the most common complaint in the gynecology clinic, accounting for more than 20% of all outpatient visits.^\[[@R12],[@R13]\]^

The clinical management of CPP depends on the patients' diagnosis.^\[[@R14],[@R15]\]^ Ultrasound has been reported to help diagnose patients with CPP accurately.^\[[@R16]--[@R21]\]^ However, no study has systematically assessed its impact for patients with CPP. Thus, in this study, we will systematically evaluate the diagnostic impact of ultrasound for patients with CPP.

2. Methods
==========

2.1. Objective
--------------

This study will aim to evaluate the impact of ultrasound in the diagnosis of patients with CPP.

2.2. Inclusion criteria for study selection
-------------------------------------------

### 2.2.1. Type of studies

This study will include case-controlled studies that evaluating the impact of ultrasound diagnosis of patients with CPP. However, we will exclude any other studies, such as animal studies, non-clinical studies, and case studies.

### 2.2.2. Type of participants

In this study, the reports of patients with laboratory examination-proven CPP will be included.

### 2.2.3. Type of index test

Index test: ultrasound will be utilized to diagnose patients with CPP. However, CPP combined with other diagnostic test will not be included.

Reference test: patients with laboratory examination-proven CPP will be considered as comparators.

### 2.2.4. Type of outcome measurements

The primary outcomes consist of sensitivity and specificity. The secondary outcomes comprise of positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

2.3. Data sources and search strategy
-------------------------------------

### 2.3.1. Electronic searches

The following databases will be comprehensively searched from inception to July 1, 2019: PUBMED, EMBASE, Cochrane Library, PSYCINFO, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and WANGFANG databases. All electronic databases will be retrieved without any language limitations. The detailed search strategy for PUBMED is presented in Table [1](#T1){ref-type="table"}. In addition, similar search strategies will be adapted to any other electronic databases.
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### 2.3.2. Other resources

We will also search conference proceedings, clinical registry, and reference lists of included studies.

2.4. Data collection and analysis
---------------------------------

### 2.4.1. Study selection

This study consists of two-stage screening process. First, the inclusion criteria will be performed by 2 independent authors to scan all titles and abstracts to check potential relevant studies. Studies will be rejected at first stage if they will not meet the eligibility criteria. Second, full literature copies of remaining studies will be reviewed to identify if they meet final selection. Any disagreements between 2 authors will be solved by consensus with the help of a third author. All study selection process will be detailed in a flow-diagram chart.

### 2.4.2. Data extraction

Two authors will independently extract data from all eligible studies according to the data extraction spreadsheet. Any differences regarding the extracted variables between 2 authors will be solved by consensus with a third author. The data extraction consists of study characteristics, study design, patient characteristics, inclusion eligibility, study methods, index and reference tests, and outcome measurements. Any attempts will be tried to inquire missing information by contacting corresponding authors of all eligible studies.

2.5. Quality assessment
-----------------------

All quality assessments of included studies will be evaluated by methodological quality will be measured by Quality Assessment of Diagnostic Accuracy Studies tool.^\[[@R22]\]^ Two authors will independently assess the methodological quality of all included studies respectively. Any discrepancies between 2 authors will be solved by discussion with a third author.

2.6. Assessment of heterogeneity
--------------------------------

Before data synthesis, we will assess the heterogeneity among eligible studies using *I*^*2*^ statistic. *I*^*2*^ ≤ 50% means low heterogeneity, while *I*^*2*^ \> 50% indicates significant heterogeneity.

2.7. Statistical analysis
-------------------------

We will use RevMan V.5.3 software and Stata V.12.0 software for statistical analysis. Specific characteristics and findings of all included studies will be illustrated in tables. Each outcome will be calculated as descriptive statistics with 95% confidence intervals. In addition, a descriptive forest plot and a summary receiver operating characteristic plot will also be carried out.

If *I*^2^ ≤ 50%, we will use Mantel--Haenszel fixed-effects model to pool the data and meta-analysis will be conducted. Otherwise, Mantel--Haenszel random-effects model will be used to pool the data, subgroup analysis will be performed and meta-regression test will be operated to identify the sources of heterogeneity before the decision of whether outcome data should be synthesized. If there is still significant heterogeneity after subgroup analysis, we will only describe outcome results instead of data pooling and meta-analysis.

2.8. Subgroup analysis
----------------------

This study will carry out subgroup analysis to identify any possible causes for significant heterogeneity based on the types of study characteristics, treatments, and controls.

2.9. Sensitivity analysis
-------------------------

We will perform sensitivity analysis to check stability of outcome results by eliminating the low methodological quality studies.

2.10. Reporting bias
--------------------

For the assessment of reporting bias, we will produce funnel plots and associated regression tests to judge the publication bias among included studies.^\[[@R23]\]^

2.11. Ethics and dissemination
------------------------------

Publication in a relevant peer-reviewed journal and dissemination is at a peer-reviewed journal. This study will not need ethic approval, because no individual data are involved.

3. Discussion
=============

No study has reported to assess the impact of ultrasound diagnosis of patients with CPP presently. This study firstly tries to systematically search and summarize the current relevant primary studies on the impact and to synthesize the effect estimates from all eligible studies. The results of this study will be likely to well inform the policy and decision making on diagnosis and healthcare for patients with CPP in the public or clinical practice.
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